Viewing Study NCT00208793



Ignite Creation Date: 2024-05-05 @ 11:59 AM
Last Modification Date: 2024-10-26 @ 9:18 AM
Study NCT ID: NCT00208793
Status: COMPLETED
Last Update Posted: 2013-11-26
First Post: 2005-09-13

Brief Title: Calcium and Vitamin D vs Markers of Adenomatous Polyps
Sponsor: Emory University
Organization: Emory University

Study Overview

Official Title: Calcium Vitamin D and Colon Cancer Risk Biomarkers
Status: COMPLETED
Status Verified Date: 2013-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: CaDvMAP
Brief Summary: The purpose of this study is to test whether calcium andor vitamin D supplementation favorably affects a set of biomarkers of risk for colon cancer in persons who are at higher than average risk for colon cancer ie have already undergone the removal of adenomatous polyps which are known to be precursors to developing colon cancer
Detailed Description: There is strong biologic plausibility and animal experimental evidence for protection against colorectal cancer by calcium and vitamin D calcium significantly reduced adenoma recurrence in a large clinical trial in humans yet the previously reported observational evidence although generally supportive is inconsistent and the observational literature strongly supports protection from vitamin D A close physiological relationship between calcium and vitamin D has long been known Yet other than a possible reduction of colorectal epithelial cell proliferation by calcium the effects of calcium and vitamin D individually or jointly on the normal human colorectal epithelium remain unknown There have been no clinical trials involving vitamin D individually or jointly with calcium related to colorectal cancer chemoprevention in humans There are currently no generally accepted pre-neoplastic biomarkers of risk for colorectal cancer other than the possible exception of proliferation markers that at best have limited usefulness as individual markers Based on recent advances in understanding the molecular basis of colorectal cancer we developed a panel of newer plausible reliable immunohistochemically detected biomarkers that provides molecular phenotyping of the normal appearing colorectal epithelium 1 inflammation COX-2 2 the expression of genes involved in the normal structure and function of the colorectal epithelium that have been found to be altered early in the two major colorectal carcinogenesis pathways APC MSH2 MLH1 and 3 a more complete picture of the cell cycle events in colorectal epithelial crypt cells short and long-term proliferation MIB-1 and telomerase differentiation p21 apoptosis inhibition and promotion bcl-2 bax and bak that has not yet been tested in a chemoprevention trial

To address these needs we will conduct a preliminary randomized double-blind placebo-controlled 2 x 2 factorial chemoprevention trial n 88 of calcium 2000 mgday and vitamin D3 800 IUday alone and in combination vs placebo over 6 months in patients with recent removal of sporadic adenomatous colorectal polyps to investigate their effects on the individual components and aggregate profile of our colorectal cancer risk biomarker panel We will also examine study results stratified by NSAID use and Bsm I vitamin D receptor genotypes The preliminary estimates of treatment effect sizes and variabilities will be used to refine the biomarker panel and study design and to calculate the needed sample size for a potential full-scale study

We assert that using biological measurements of risk as they have for ischemic heart disease will result in a decline in colorectal cancer incidence and mortality The proposed project is borne of this vision and has intertwined missions of exploring the efficacy of two plausible and evidentially well-supported dietary agents calcium and vitamin D on the modulation of a plausible panel of molecular phenotypic biomarkers of risk for colorectal neoplasia

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
R01CA104637 NIH None httpsreporternihgovquickSearchR01CA104637